These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12654666)

  • 1. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
    Colonno RJ; Thiry A; Limoli K; Parkin N
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1324-33. PubMed ID: 12654666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
    Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 protease mutations and protease inhibitor cross-resistance.
    Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
    Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
    J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
    Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
    Hertogs K; Bloor S; Kemp SD; Van den Eynde C; Alcorn TM; Pauwels R; Van Houtte M; Staszewski S; Miller V; Larder BA
    AIDS; 2000 Jun; 14(9):1203-10. PubMed ID: 10894285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
    Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
    BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
    Schmidt B; Korn K; Moschik B; Paatz C; Uberla K; Walter H
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3213-6. PubMed ID: 11036057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.
    Schmidt B; Walter H; Moschik B; Paatz C; van Vaerenbergh K; Vandamme AM; Schmitt M; Harrer T; Uberla K; Korn K
    AIDS; 2000 Aug; 14(12):1731-8. PubMed ID: 10985309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
    Schnell T; Schmidt B; Moschik G; Thein C; Paatz C; Korn K; Walter H
    AIDS; 2003 May; 17(8):1258-61. PubMed ID: 12819531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
    Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.